Quantcast
Channel: Daniel Headlines on One News Page
Viewing all 49070 articles
Browse latest View live

The double-life of a Crowborough builder whose hobby is mingling with Hollywood superstars

$
0
0
The double-life of a Crowborough builder whose hobby is mingling with Hollywood superstars David James, 51, has met a string of famous actors like Chris Pratt, Hugh Jackman and Daniel Radcliffe Reported by Canterbury Times 13 hours ago.

American Association of Oral and Maxillofacial Surgeons Presents Awards During 100th Annual Meeting

$
0
0
During its 100th anniversary celebration, the American Association of Oral and Maxillofacial Surgeons (AAOMS) honored more than 20 of its members for their contributions to the specialty through their outstanding research, education and advocacy.

CHICAGO (PRWEB) November 01, 2018

During its 100th anniversary celebration, the American Association of Oral and Maxillofacial Surgeons (AAOMS) honored more than 20 of its members for their contributions to the specialty through their outstanding research, education and advocacy.

The awards were presented Oct. 10 during the Opening Ceremony of the 100th AAOMS Annual Meeting, Scientific Sessions and Exhibition – the largest gathering of oral and maxillofacial surgeons in the country – at the Hilton Chicago.

The Annual Meeting was dedicated to the association’s fellows and members. More than 9,000 oral and maxillofacial surgeons in the United States compose the professional organization, which was founded in 1918 in Chicago.

Notably, AAOMS bestowed its Robert V. Walker Distinguished Service Award – which recognizes fellows and members for long-standing contributions to the specialty through clinical, academic, research or public service – to Bruce Epker, DDS, Ph.D., M.S.D., of Weatherford, Texas.

He is credited with pioneering a pathway for OMSs to perform orthognathic surgery, craniofacial surgery and cosmetic surgery, allowing these surgeons to gain access to hospital privileges. He trained a generation of residents at John Peter Smith Hospital in Fort Worth, Texas, where he was chair of the division of OMS.

Dr. Epker also served as director of the Center for the Correction of Dentofacial Deformities and the Fort Worth Cleft Palate Center at John Peter Smith Hospital. He has authored several textbooks considered benchmarks in the field and more than 100 peer-reviewed articles.

Other award winners include:· Board of Trustees Special Citation Award – Andrew Herlich, DMD, M.D., of Pittsburgh, Pa.
· Clinical Research Award – Deepak Krishnan, DDS, FACS, of Cincinnati, Ohio
· Committee Person of the Year Award – David Stanton, DMD, M.D., FACS, of Philadelphia, Pa.
· Daniel M. Laskin Award for an Outstanding Predoctoral Educator – Dean DeLuke, DDS, MBA, of Richmond, Va.
· Donald B. Osbon Award for an Outstanding Educator – John Zuniga, DMD, Ph.D., M.S., of Dallas, Texas
· Faculty Educator Development Awards – Andrea Burke, DMD, M.D., Seattle, Wash.; Paul Deitrick, DMD, M.D., Philadelphia, Pa.; Courtney Jatana, DDS, M.S., FACS, Columbus, Ohio; Leonel Perez Jr., DDS, M.D., Germantown, Md.; and Andrew Read-Fuller, DDS, M.D., M.S., Dallas, Texas
· Honorary Fellowship – Christopher Robinson, DDS, of Edmonton, Alberta
· Humanitarian Awards for Fellows and Members – Jerry Halpern, DDS, of New York, N.Y.; and David Hoffman, DDS, FACS, of Staten Island, N.Y.
· Humanitarian Awards for Residents – Wade Barker, DDS, M.D., Dallas, Texas; Patrick Christopher, DDS, M.D., Kansas City, Mo., and Abigail Estelle, DDS, M.D., Jacksonville, Fla.
· John F. Freihaut Political Activist Award – Charles Crago, DMD, M.D., of Fargo, N.D.
· Outstanding Legislator of the Year Award – Congressman Earl L. “Buddy” Carter (R-Ga.)
· Presidential Achievement Award – David Todd, DMD, M.D., of Lakewood, N.Y.
· Resident Scientific Awards – Brian Christensen, DDS, M.D., New Orleans, La.; Rodney Nishimoto, DMD, M.D., Seattle, Wash.; and Keith Sonneveld, DDS, Fort Lauderdale, Fla.
· Special Honorary Fellowship – Ian Martin, BDS, MBBS (Hons), LLM, FDSRCS, FRCS, president of the British Association of OMS
· William J. Gies Foundation Award – George Obeid, DDS, of Washington, D.C.

The experts in face, mouth and jaw surgery® — The American Association of Oral and Maxillofacial Surgeons (AAOMS) is the professional organization representing more than 11,000 oral and maxillofacial surgeons, OMS residents and OMS professional staff in the United States. AAOMS supports its fellows’ and members’ ability to practice their specialty through education, research and advocacy. AAOMS fellows and members comply with rigorous continuing education requirements and submit to periodic office anesthesia evaluations. For additional information about oral and maxillofacial surgery, visit the AAOMS websites at https://AAOMS.org and https://myOMS.org.

CONTACT: Jolene Kremer, Associate Executive Director, Communications & Publications,
American Association of Oral and Maxillofacial Surgeons
Phone: 847-233-4336
Fax: 847-678-6286
jkremer(at)aaoms(dot)org
AAOMS.org Reported by PRWeb 13 hours ago.

Lion Air boss can't understand why people are scared of using airline

$
0
0
Lion Air boss can't understand why people are scared of using airline Daniel Adi said there is 'no reason' for people to fear using Lion Air despite admitting he has no idea what caused one of the carrier's nearly-new planes to fall out of the sky near Jakarta on Monday. Reported by MailOnline 12 hours ago.

The cold and flu remedies these nine experts swear by

$
0
0
The cold and flu remedies these nine experts swear by Dr Daniel Glass, a dermatologist on London's Harley Street, says carrots and celery in chicken soup contain beta-carotene, which supports the immune system and fight off infections. Reported by MailOnline 12 hours ago.

CloudMargin appoints Daniel Schwartz as chief information officer

$
0
0
CloudMargin, the award-winning creator of the world’s first and only collateral and margin managemen... Reported by Finextra 11 hours ago.

The Daniel Arzani riddle as Celtic starlet posts worrying pictures

$
0
0
The Daniel Arzani riddle as Celtic starlet posts worrying pictures Aussie had to be stretchered off with a knee injury during the 5-0 hammering of Dundee. Reported by Daily Record 10 hours ago.

Actor Edward Norton's startup wants to fix the way TV ads are measured, and a handful of ad-tech investors have put millions behind it

$
0
0
Actor Edward Norton's startup wants to fix the way TV ads are measured, and a handful of ad-tech investors have put millions behind it· *Edo is a data and measurement startup with a database of 47 million television airings that helps marketers analyze the creative and placement of their TV ads.*
· *Edward Norton and Daniel Nadler founded the firm, which has raised $12 million in Series A funding.*
· *The TV-tech industry is exploding in terms of funding and a growing number of firms promise advertisers granular stats about their TV campaigns.*Investors are betting big on companies that promise to fundamentally shake up TV advertising, and another startup just snagged a sizeable round.

The TV-geared analytics and measurement company, Edo, has secured $12 million in Series A funding, led by Breyer Capital. A handful of advertising players including Brian Sheth and Robert Smith (Vista Equity co-founders) and WGI Group (founded by Jonah Goodhart, Noah Goodhart, and Michael Walrath) also participated in the round.

Actor and filmmaker Edward Norton and Daniel Nadler founded Edo in 2015 to match up granular TV ratings with purchase intent data through machine learning. 

"We had seen that the legacy media companies were getting disrupted by Netflix and Amazon who were using organic data capabilities as significant advantages," Norton said. "At the same time networks were facing the assertion by Google and Facebook that digital advertising was more effective, and none of the legacy measurement players were really helping them challenge that with sophisticated data."

Edo's goal is to amass a huge library of data pulled from TV networks to help determine how likely someone is to buy a product after watching an ad, based on data about how similar ads have performed in the past.

The company claims to have a database with access to 47 million TV airings across 80 categories of advertising and 2,100 brands. Edo's clients include ESPN, Turner, NBCUniversal, Paramount and Lionsgate.

*Read more*: Ad execs are deeply skeptical that TV measurement will ever catch up to digital — putting comScore and Nielsen on notice and billions on the line

"Our ultimate goal is to be an alternative currency to the way that TV advertising is bought and sold," said Edo CEO Kevin Krim. "We can run very advanced data-science models to develop expected norms of responses," Krim said. In other words, Edo can construct a baseline estimate to compare an ad's performance with.

Krim said that after marketers run a few dozen airings of an ad, Edo can analyze how that piece of creative compares against its database and can determine if it is over-performing or under-performing.

*Movie marketers run lots of ads without a lot of data behind them*

Film studios are an example of an entity that could benefit from measurement like Edo's. Movie marketers spend millions of dollars blasting commercials across multiple networks leading up to a film premiere.

According to Krim, a movie marketer can run 4,000 to 6,000 TV ads weeks before a film premieres with dozens of creatives. Edo scores each of those ads to determine which creative and networks are most likely to increase the chance that a person will buy a movie ticket.

"They're a real crucible of invention because they have to deliver millions of consumers [to a movie theater] on a single weekend or their product will be an economic failure," Krim said.

Or take the example of an automaker launching a campaign for a SUV for the first time. Edo can dig through data to understand what types of creative and placements have worked well in the past for other automakers.

*The TV measurement industry is rapidly changing*

Edo is one of a handful of tech companies all eyeing the $70 billion TV industry. As more ad budgets get funneled to digital, marketers are increasingly looking to plug data and technology into their ad buys to serve targeted TV ads and then measure how effective they are in getting people to take an action, like buying something or visiting a website.

Firms like VideoAmp, iSpot, and Simulmedia are also all working to innovate in TV advertising. VideoAmp, for example, uses software to help brands determine how they should divvy up ad budgets between TV and digital. And Simulmedia rolled out a marketplace this week aimed at helping small, digital-first brands buy TV placements through automated software.

For Edo, the company wants to work with both buyers and sellers.

"We've done a ton of research that allows us to give very high-fidelity views into how every creative that a TV marketer has on-air is effective at driving consumers to be more likely to buy the products that are being advertised," Krim said.

Join the conversation about this story »

NOW WATCH: What activated charcoal actually does to your body Reported by Business Insider 10 hours ago.

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

$
0
0
· Oral presentation highlighting updated THINK study data evaluating CYAD-01 without preconditioning chemotherapy in relapsed or refractory (r/r) acute myeloid leukemia (AML)
· As of July 2018, three out of seven (42%) r/r AML patients evaluable for response achieved a complete response (CRh/CRi) following treatment with the per-protocol dose of CYAD-01
· Overall, five out of seven (71%) patients achieved meaningful decrease in bone marrow blasts
· Company to host Analyst/Investor event on Monday, December 3, 2018

MONT-SAINT-GUIBERT, Belgium, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies, today announced that two abstracts detailing updated clinical results from the Phase 1 THINK dose-escalation trial and anticipated clinical trials for the CYAD-01 program will be presented at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, December 1-4, 2018. Company management will also review the results of the THINK trial and provide an update on Celyad’s clinical development program for CYAD-01 at an Analyst/Investor event, which will also be available via webcast on December 3, 2018.

“We are encouraged by the preliminary THINK study data evaluating CYAD-01, without preconditioning chemotherapy in patients with relapsed or refractory acute myeloid leukemia,” said Dr. Christian Homsy, CEO of Celyad. “The data supplement a growing body of evidence that CYAD-01 shows encouraging clinical activity and is well-tolerated and suggests its potential for the treatment of acute myeloid leukemia, a challenging disease with limited therapeutic options. In addition to this important milestone, we continue to investigate CYAD-01 in alternative protocols to further optimize its clinical benefit.”

Updated data from the THINK trial of CYAD-01 in patients with r/r AML will be presented by Principal Investigator David A. Sallman, M.D., of the Moffitt Cancer Center, on December 3, 2018. The presentation will include new information on safety, activity and correlative science data of the complete dose-escalation segment of the trial.

Top-line data from the abstract as of a data cut-off date of July 31, 2018, included:

· Of the seven response-evaluable r/r AML patients enrolled in the trial who received the per-protocol dose of CYAD-01, the best overall response rate was 42% (three patients). Two additional patients experienced important clinical benefit with hematologic improvement and bone marrow blasts decrease, leading to clinical activity of 71% (five patients).
 
· One patient experienced a complete remission with partial hematologic recovery (CRh) and two patients experienced a complete remission with incomplete marrow recovery (CRi). One CRh and one CRi occurred at dose level 1 (DL1) with an additional CRi at dose level 3. All three responders achieved a response by day 29 (i.e., prior to the third administration of CYAD-01).
 
· The patient with CRh from DL1 was bridged to allogeneic hematopoietic stem cell transplantation (allo-HSCT) on day +97 post treatment with CYAD-01. This patient remains in durable complete molecular remission (CR[MRD-]) for more than one year (ongoing). A detailed case report of this patient was published in Haematologica in April 2018.
 
· Of the two additional r/r AML patients who experienced a clinical benefit, one patient had a decrease in blast counts from 24% to 10%, while a second patient had a decrease from 9.8% to 5.5%. Disease stabilization in these patients were observed for three months and over four months (ongoing), respectively. Both patients were treated in dose level 2 of the study.
 
· Overall, 12 patients with hematological malignancies (AML, myelodysplastic syndrome and multiple myeloma) treated with CYAD-01 in the cohort had reached the safety follow-up. The most common treatment-related adverse events (AEs) included pyrexia, cytokine release syndrome (CRS), hypoxia, lymphopenia, fatigue and nausea. CRS occurred in five patients (three grade 1/2 AEs and two grade 3 AEs), with rapid resolution following the appropriate treatment, including tocilizumab. Overall, five patients experienced grade 3/4 treatment-related AEs. No neurotoxicity AEs were observed in patients treated with CYAD-01.

CYAD-01 and THINK Trial Design
CYAD-01 is an investigational CAR-T therapy in which a patient's T cells are engineered to express the chimeric antigen receptor NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands expressed on tumor cells.

The THINK trial (NCT03018405) is an open-label, dose-escalation Phase 1 trial assessing the safety and clinical activity of multiple CYAD-01 administrations without prior preconditioning in two parallel cohorts: i) patients with hematological malignancies, including r/r AML, and ii) patients with metastatic solid tumors. The dose escalation segment of the study evaluates three dose levels (300 million, 1 billion and 3 billion cells per injection) of one cycle of three CYAD-01 administrations with two-week intervals.

ASH Analyst/Investor Event and Webcast Information
Celyad will host an Analyst/Investor event on Monday, December 3, 2018, beginning at 8:30 p.m. PT to review data presented at ASH. The event will be webcast live and can be accessed under Events & Webcasts in the Investors section of the Company’s website.

A complete list of Celyad and collaborator presentations to be made at ASH appears below:

Oral Presentation
Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy Without a Prior Preconditioning Chemotherapy (Abstract #111326 – Publication Number 902)

Presenter: David A. Sallman, M.D., Moffitt Cancer Center
Date: Monday, December 3, 2018, 4:45 p.m. Pacific Time
Location: Manchester Grand Hyatt San Diego, Seaport Ballroom F

Poster Presentation
Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia (Abstract #114747 – Publication Number 1398)

Presenter: Jason B Brayer, MD, Moffitt Cancer Center
Date: Saturday, December 1, 2018, 6:15 PM - 8:15 PM
Location: San Diego Convention Center, Hall GH

*About Celyad *

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), is currently evaluated in a Phase I dose escalation clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). The safety and clinical activity of the CYAD-01 therapy concurrently administered with standard-of-care treatments or preconditioning chemotherapy is also assessed in a full clinical development program focused on acute myeloid leukemia and colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the NASDAQ Global Market, all under the ticker symbol CYAD.

**For more information, please contact:**

*Celyad*
*Investors@celyad.com*
*Filippo Petti, Chief Financial Officer** *

*Communications@celyad.com*
*Carri Duncan, PhD, VP Corporate Development & Communications - *T: +32(0) 10 39 41 58
*For Belgium: Comfi*
*Sabine Leclercq - *T.: +32 (0)2 290 90 91 – *celyad@comfi.be*
*For France: NewCap*
*Pierre Laurent and Nicolas Mérigeau - *T: + 33(0)1 44 71 94 94 * -* *celyad@newcap.eu*
*For the U.S.: LifeSci Advisors*
*Daniel Ferry –* T.: +1 (617) 535 7746* – **daniel@lifesciadvisors.com*
*Public Relations: Allison Blum* – T:+1 (646) 627 8383* -* *allison@lifescipublicrelations.com*

*Forward-looking statements*

This release may contain forward-looking statements, including statements regarding the safety and efficacy of CYAD-01 and the mAb manufacturing method used to manufacture this drug product candidate; statements concerning the ongoing and planned clinical development of CYAD-01, including the timing of data readouts and presentations; the clinical and commercial potential of CYAD-01 and the adequacy of Celyad’s financial resources; Celyad’s financial condition, results of operation and business outlook; and Celyad’s expected cash burn. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual results, financial condition and liquidity, performance or achievements of Celyad, or industry results, to differ materially from those expressed or implied by such forward-looking statements. In particular it should be noted that the data summarized above are preliminary in nature. There is limited data concerning safety and clinical activity following treatment with the CYAD-01 drug product candidate. These results may not be repeated or observed in ongoing or future studies involving the CYAD-01 drug product candidate. These forward-looking statements are further qualified by important factors and risks, which could cause actual results to differ materially from those in the forward-looking statements, including statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance drug product candidates into, and successfully complete, clinical trials; our ability to successfully manufacture drug product for our clinical trials, including with our mAb manufacturing process and with respect to manufacturing drug product with the desired number of T cells under our clinical trial protocols; our reliance on the success of our drug product candidates, including our dependence on the regulatory approval of CYAD-01 in the United States and Europe and subsequent commercial success of CYAD-01, both of which may never occur; the timing or likelihood of regulatory filings and approvals; our ability to develop sales and marketing capabilities; the commercialization of our drug product candidates, if approved; the pricing and reimbursement of our drug product candidates, if approved; the implementation of our business model, strategic plans for our business, drug product candidates and technology; the scope of protection we are able to establish and maintain for intellectual property rights covering our drug product candidates and technology; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; cost associated with enforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims; regulatory development in the United States, the European Union, and other jurisdictions; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; our ability to maintain and establish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug product candidates, if approved; our financial performance; developments relating to our competitors and our industry, including competing therapies and statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance. A further list and description of these risks, uncertainties and other risks can be found in Celyad’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on April 6, 2018 and subsequent filings and reports by Celyad. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document and Celyad’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.  Reported by GlobeNewswire 10 hours ago.

What you need to know in advertising today

$
0
0
What you need to know in advertising today Investors are betting big on companies that promise to fundamentally shake up TV advertising, and another startup just snagged a sizeable round.

The TV-geared analytics and measurement company, Edo, has secured $12 million in Series A funding, led by Breyer Capital. A handful of advertising players including Brian Sheth and Robert Smith (Vista Equity co-founders) and WGI Group (founded by Jonah Goodhart, Noah Goodhart, and Michael Walrath) also participated in the round.

Actor and filmmaker Edward Norton and Daniel Nadler founded Edo in 2015 to match up granular TV ratings with purchase intent data through machine learning.

*Click here* to read more about Edo.

*In other news:*

*These 3 charts show why there's more good days ahead for e-commerce — and more bad times for traditional retailers.* Online stores are continuing to gain share against their brick-and-mortar counterparts, Morgan Stanley details in a new report.

*Coca-Cola is in talks to invest in Dirty Lemon, a direct-to-consumer company known for its trendy drinks, and the CEO says the startup is dropping its CBD-infused beverage.* Dirty Lemon is currently raising a round of funding that reportedly includes investors like Betaworks and Winklevoss Capital.

*Starbucks' revamped red cups are back despite past scandals — here's what they look like this year.* The coffee chain is kicking off the holiday season on November 2, with the return of seasonal menu items, festive decor, and the 2018 red cups, which come in four varieties.

*Facebook warned Wall Street that it's going to spend a lot of money fixing problems that can never be fixed.* UBS forecasts that Facebook's costs and expenses of more than $20 billion could grow by as much as 50% next year, partly because of investment in security.

*20-year-old 'influencer' sued for allegedly refusing to wear Snap Spectacles in public despite being paid $45,000.* According to the lawsuit, the contract required him to publish Instagram posts and stories of himself wearing the spectacles during the New York, Milan, or Paris fashion weeks. The PR agency's client was Snap Inc.

*Spotify sinks after delivering disappointing revenue guidance. *The company's fourth-quarter revenue guidance fell short of Wall Street estimates, and shares dropped more than 5% ahead of Thursday's opening bell.

Join the conversation about this story »

NOW WATCH: Scorpion venom is the most expensive liquid in the world — here's why it costs $39 million per gallon Reported by Business Insider 9 hours ago.

November 27th MGT Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against MGT Capital Investments, Inc. – MGTI

$
0
0
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important November 27, 2018 lead plaintiff deadline in the shareholder class action lawsuit against MGT Capital Investments, Inc.* *(“MGT” or the “Company”) (OTCMKTS: MGTI). The lawsuit seeks to recover damages on behalf of those who purchased the securities of MGT between October 9, 2015 and September 7, 2018, both dates inclusive (the “Class Period”).If you purchased MGT securities, and/or would like to discuss your legal rights and options, please visit MGT Shareholder Class Action Lawsuit or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a pump-and-dump scheme to artificially inflate MGT’s stock price; (2) this illicit scheme caused MGT to make false and misleading statements, which would result in governmental scrutiny, including from the SEC; (3) certain of the scheme defendants exercised control over MGT and its management; (4) consequently, the illicit scheme would ultimately cause MGT’s stock to become delisted from the NYSE MKT; and (5) as a result, defendants’ statements about MGT’s business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On September 7, 2018, the U.S. Securities and Exchange Commission (“SEC”) filed a lawsuit against a former officer of MGT as well as other individuals and corporations, alleging violations of the federal securities laws. The SEC complaint alleges that defendants were participants in “highly profitable ‘pump-and-dump’ schemes…from 2013 through 2018” in the stock of three public companies, including MGT. The SEC complaint further alleges that the schemes “enrich[ed] Defendants by millions of dollars, [and] left retail investors holding virtually worthless shares.”

On this news, MGT stock fell $0.195 per share, or over 33%, over the next two trading days to close at $0.395 per share on September 10, 2018, damaging investors.

If you wish to serve as lead plaintiff, you must move the Court no later than November 27, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased MGT securities, and/or would like to discuss your legal rights and options, please visit https://www.bernlieb.com/cases/mgt-capital-investments-inc-mgti-lawsuit-class-action-fraud-stock-85/ or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Daniel Sadeh
Bernstein Liebhard LLP
http://www.bernlieb.com
(877) 779-1414
dsadeh@bernlieb.com Reported by GlobeNewswire 9 hours ago.

I-MED Pharma Partners with Iogen Oy to Introduce I-DROP®, I-LID ’N LASH®, I-RELIEF™ Therapeutic Eye Mask and the I-PEN® Osmolarity System to the Finnish Market

$
0
0
MONTREAL, Nov. 01, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is pleased to announce the signing of an exclusive distribution agreement with Iogen Oy for its I-DROP^® and I-LID ’N LASH^® product lines, as well as the I-RELIEF^TM HOT & COLD THERAPY EYE MASK with THERMABEADS^TM and the I-PEN^® Tear Osmolarity System.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/79e63011-9c51-4efd-955d-e5344050359dI-MED Pharma continues to expand access of their cutting edge OSD line through a new distribution partnership with Iogen Oy in Finland. This is in alignment with the international growth strategy that the company has defined moving forward.Tero Rinne, Chairman of the Board of Iogen Oy commented, "We are exceedingly happy about starting our cooperation with I-MED Pharma, whose category defining products will provide great value to Finnish ophthalmologists. The diagnostic platform will also allow us to better serve our patients with more accurate therapeutic planning."

Daniel Hofmann, President of I-MED Pharma stated, “We are thrilled to be partnering with Iogen Oy, a company that shares our vision for providing both eye care professionals and dry eye patients with innovative, value-added products.  We are excited that this partnership will allow for expanded access of our dry eye product line in the Finnish market and we look forward to working closely with Iogen Oy over the next several months to ensure a successful launch.”

*About I-MED Pharma*

I-MED Pharma Inc. is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists and the global eye care community. Established almost thirty years ago, I-MED Pharma creates and distributes innovative medical, surgical and veterinary eye care products worldwide. It continually researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degeneration, dry eye, glaucoma and meibomian gland dysfunction.

I-MED Pharma is proud to have been at the forefront of managing Dry Eye Syndrome as a serious disease and invests heavily into education and developing effective dry eye products.  I-MED Pharma’s ocular surface disease product range includes diagnostic tools, dry eye drops, ocular hygiene, nutrition and therapeutic accessories.

About Iogen Oy

Iogen Oy is the largest independent supplier in Finland for ophthalmic medical and surgical devices. The primary focus is on delivering innovations and high technology, complemented by customer-centric, consultative salesmanship based on true expertise. We are constantly looking for companies that fulfill our requirements of being innovative and bringing added value to our customers.

For more information, please email media@imedpharma.com or visit imedpharma.com. Reported by GlobeNewswire 8 hours ago.

Liverpool news: Watch Daniel Sturridge’s amazing no-look goal scored in training

$
0
0
Daniel Sturridge gave Jurgen Klopp another glimpse of his incredible talent by scoring a ‘no-look’ goal during a Liverpool training session. Sturridge, the England forward, has re-established himself as a key member of Klopp’s first-team squad this season having finally returned to full fitness. He’s already scored four goals in just 11 matches, helping the […] Reported by talkSPORT 8 hours ago.

Blue Ocean Acquires the Pikesville DoubleTree by Hilton Hotel and Conference Center

$
0
0
Blue Ocean has strategically expanded its real estate portfolio by acquiring its first hospitality project – the 171 room, DoubleTree by Hilton Hotel and Conference Center in Pikesville, MD.

PIKESVILLE, Md. (PRWEB) November 01, 2018

Blue Ocean has strategically expanded its real estate portfolio by acquiring its first hospitality project – the 171 room, DoubleTree by Hilton Hotel and Conference Center in Pikesville, MD. In addition to the hotel, the 10-acre site also includes a 50,000 square foot indoor tennis and fitness facility, as well as 32,000 square feet of office and retail buildings.

Located at 1726 Reisterstown Road in Baltimore County, the well-placed property sits at the intersection of Interstate 695 and Reisterstown Road (State Highway 140). This strategic location provides unparalleled convenience and access for the mix of patrons that frequent the site, as well as exposure to over 220,000 commuters per day.

This latest acquisition reflects Blue Ocean’s strategy to further diversify its portfolio, while highlighting the most stable and irreplaceable properties that the Mid-Atlantic market has to offer. The property is poised for various improvements and renovations through a substantial redevelopment program that Blue Ocean intends to implement in the coming months.

Blue Ocean President Jonathan Ehrenfeld states, “The DoubleTree project provides Blue Ocean with secure and valuable diversification beyond traditional multi-family and industrial investments. We are excited to enhance this project and to provide Baltimore with a premier hotel and event space experience. Our team is dedicated to unlocking the amazing potential that this property has to offer Baltimore and the surrounding region.”

As part of the immediate improvement plans, the hotel and conference center will receive substantial renovations. Additional planning and development are underway to breathe new life into the tennis, fitness, office, and retail facilities. Details regarding those renovations as well as the innovative retail and dining experiences within the DoubleTree by Hilton Hotel and Conference Center will be forthcoming in the near future.

Blue Ocean was assisted in the acquisition by commercial real estate professionals, Steven Cornblatt and Gary Olschansky of Trout Daniel & Associates. The ‘off-market’ transaction was made available through the connections of the organizations’ vast network. Leasing and consulting services by Trout Daniel & Associates are expected to continue as the project evolves in the coming years.

About Blue Ocean:
Blue Ocean is a property management company in Baltimore, MD that is active in syndicating, purchasing and managing investment grade real estate assets in the multifamily, office, retail and industrial sectors. The Company was founded in 2004. Since that time Blue Ocean has grown its portfolio to over 27 properties valued at over $425,000,000. The Blue Ocean portfolio consists of approximately 3,700 apartment homes and 2,000,000 square feet of commercial space. Reported by PRWeb 8 hours ago.

Millennials are buying the Apple dip ahead of earnings (APPL)

$
0
0
Millennials are buying the Apple dip ahead of earnings (APPL)· *Apple will report its third-quarter results after Thursday's closing bell.*
· *Shares have fell as much as 11.5% from their October 3 peak as the Nasdaq witnessed its heaviest selling since the financial crisis.*
· *Investors on Robinhood, a free-trading app popular among younger traders, have been snapping up shares.*
· Watch Apple trade live.

Apple is set to report its third-quarter earnings after Thursday's closing bell and investors on Robinhood, a no-fee trading app popular among younger traders, are buying the stock's dip ahead of the results. 

The smartphone giant faced a brutal sell-off in October, when the tech-heavy Nasdaq index tumbled 9.2%, posting its worst month since the financial crisis. During the selling, Apple dropped as much as 11.5% from its record peak of $233.47 set on October 3. While shares have rebounded a bit, they are still 6.4% below their all-time high. 

And while the market began to take a turn for the worst in early October, Robinhood investors waited until October 10 to begin buying shares. According to Robinhood data tracked by Business Insider, more than 6,000 users have added Apple shares over the past three weeks. A total of 185,208 Robinhood investors currently hold the stock, making it the second most-popular stock on the app, just below Ford.

It has been a memorable year for Apple, which became the first publicly traded US company to hit a $1 trillion valuation. Since crossing the milestone, Apple announced a slew of new iPhones including the iPhone XS, Apple Watch 4, and an updated iPad Pro. 

And in a recent note sent out to clients, Wedbush analyst Daniel Ives said the tech giant has the chance to be a $1.5 trillion behemoth based on his analysis of "the monetization potential of its unparalleled consumer installed base over the coming years coupled by further multiple expansion around the services business."

When Apple's results are released after the bell on Thursday, traders will be paying close attention to whether the company's fundamentals can support a continuing boost. So far among FAANG companies that have already reported, Facebook and Amazon both warned of a potential slowdown ahead. 

Apple is expected to earn an adjusted $2.78 a share on revenue of $61.4 billion, according to analysts surveyed by Bloomberg. Their average price target is $237.60 — 8% above where shares are trading on Thursday.

Apple was up 27% this year.

*Read more stories on FAANG stock earnings:*

· 'Not as spooky as feared, but ghosts remain': Here's what Wall Street is saying about Facebook's decelerating growth
· 'Every rockstar needs a break': Here's what Wall Street is saying about Amazon's disappointing guidance
· 'Long-term fundamental trends remain very, very, very much intact': Here's what Wall Street is saying about Netflix's record subscriber growth

*Now read:*

· Earnings season has been unusually terrible for many companies — here’s what investors are rewarding, and how to get in on the action

Join the conversation about this story »

NOW WATCH: This company spent 10 years developing a product that allows humans to scale walls like a gecko Reported by Business Insider 6 hours ago.

'For years my Down's syndrome son was sad no trick-or-treaters came...but they made this Halloween FANTASTIC'

$
0
0
'For years my Down's syndrome son was sad no trick-or-treaters came...but they made this Halloween FANTASTIC' Few callers came to visit Daniel until his family made an appeal on social media Reported by Derby Telegraph 6 hours ago.

Grupo Salinas Presents the 13th Caminos de la Libertad Essay Awards to Support Freedom

$
0
0
*Armando Ribas received the Una Vida por la Libertad award **from Ricardo Salinas and Sergio Sarmiento*

MEXICO CITY, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Grupo Salinas, a group of dynamic, fast-growing and technologically advanced companies, deeply committed to the modernization of the countries where they operate, announced today it held the 13^thCaminos de la Libertad Essay Awards.

During the event, Ricardo Salinas commented, “We cannot deny that the global environment is adverse to libertarian culture.” He added that in the case of Mexico there are three factors that threaten freedom: "Violence, ignorance and corruption. And what do these problems have in common? The state! There are many laws, but there is no law." He also emphasized the importance of continuing to preserve forums that promote freedom.

In the company of Sergio Sarmiento, Director of Caminos de la Libertad, Mr. Salinas presented the award Una vida por la libertad (A life for freedom) to the jurist and writer Armando Ribas, defender of tolerance and balance in human relations.

"I would like to congratulate the Caminos de la Libertad initiative for its primary role in the struggle for freedom and emotionally thank you for the award," commented the author of books such as: Monetary Theory, Inflation and Interest Rates; The Role of the Entrepreneur in Society; Between Freedom and Servitude; and Cuba: Between Independence and Freedom.

In its thirteenth edition of the Caminos de la Libertad Essay Contest, 453 works were received from Uruguay, Peru, Argentina, Cuba, Australia, Venezuela, Mexico, Spain, Guatemala, Bolivia, Ecuador, El Salvador, Chile, Trinidad and Tobago, United, France, the Dominican Republic and Brazil.

First place was awarded to the Argentinean Ricardo Manuel Rojas for his work Individuo y sociedad. ¿Ciencias sociales o ciencia de la sociedad? (Individual and Society. Social Sciences or Society Science?) with a US$15,000 prize. Second place was for the Argentinean Alejandro Bongiovanni with his work En el nombre del padre (In the Name of the Father) with US$10,000. Third place was for the Chilean Valentina Verbal Stockmeyer with the work Feminismo y liberalismo en la historia de occidente: ¿Una relación imposible? (Feminism and Liberalism in the Western History: An Impossible Relationship?) with US$5,000.

Caminos de la Libertad is a Grupo Salinas initiative promoted by Ricardo Salinas since 2005 with the aim of opening a space for discussion, expression and feedback on the issue of freedom to promote positive societal change.

*About Grupo Salinas*

Grupo Salinas (www.gruposalinas.com) is a group of dynamic, fast growing, and technologically advanced companies focused on creating: economic value through market innovation and goods and services that improve standards of living; social value, to create social capabilities to improve communities; and environmental value, by reducing the negative impact of business activities. Created by Mexican entrepreneur Ricardo B. Salinas (www.ricardosalinas.com), Grupo Salinas operates as a management development and decision forum for the top leaders of member companies. These companies include: TV Azteca (www.TVazteca.com; www.irtvazteca.com), Grupo Elektra (www.grupoelektra.com.mx), Banco Azteca (www.bancoazteca.com.mx), Advance America (www.advanceamerica.net), Afore Azteca (www.aforeazteca.com.mx), Seguros Azteca (www.segurosazteca.com.mx), Punto Casa de Bolsa (www.puntocasadebolsa.mx), Totalplay (www.totalplay.com.mx) and Totalplay Empresarial (http://totalplayempresarial.com.mx). TV Azteca and Grupo Elektra trade on the Mexican Stock Market and are part of its Sustainability Index. Each of the Grupo Salinas companies operates independently, with its own management, board of directors and shareholders. Grupo Salinas has no equity holdings. The group of companies share a common vision, values and strategies for achieving rapid growth, superior results and world-class performance.

*Press Relations:*

Luciano Pascoe, +52 (55) 1720 1313 ext. 36553, lpascoe@gruposalinas.com.mx
Daniel McCosh, +52 (55) 1720-0059, dmccosh@gruposalinas.com Reported by GlobeNewswire 6 hours ago.

Sonya Yoncheva's "Medea" casts her spell on Berlin

$
0
0
In her 50th role, the Bulgarian soprano unites with Daniel Barenboim in an unforgettable opera. Reported by euronews 5 hours ago.

Claude Puel reveals Leicester City's Daniel Amartey is facing lengthy spell on sidelines

$
0
0
The 23-year-old has undergone surgery on his ankle Reported by Leicester Mercury 3 hours ago.

Sport24.co.za | 'Only' Ricciardo knows if his regrets Renault swap

$
0
0
Suffering his eighth retirement of this season, Christian Horner says "only Daniel" Ricciardo can say whether he is beginning to regret his Renault move. Reported by News24 3 hours ago.

Gap in privacy law leaves elections open to 'misuse' of personal information: privacy commissioner

$
0
0
The next federal election will face "important risks" unless Parliament makes political parties subject to privacy law, Privacy Commissioner Daniel Therrien warned Thursday. Reported by CBC.ca 3 hours ago.
Viewing all 49070 articles
Browse latest View live




Latest Images